by EmpathiCSubstanceS | Apr 25, 2021 | Cannabis Marijuana, CBC, Psilocybin Magic Mushroom
A new review from neuroethicist Eddie Jacobs, and published in the Journal of Psychedelic Studies, is suggesting psilocybin may have great potential as a treatment for obsessive-compulsive disorder (OCD). Jacobs, from King’s College London and the University of...
by EmpathiCSubstanceS | Apr 25, 2021 | Addiction, Cannabis Marijuana, CBC
Positive results from the world’s first clinical trial testing the potential for cannabidiol (CBD) to treat cannabis addiction suggest daily use of medical-grade CBD is both safe and effective at reducing problematic cannabis consumption. The researchers quickly...
by EmpathiCSubstanceS | Apr 25, 2021 | Psilocybin Magic Mushroom
After waiting more than 100 days for a response, four terminally ill cancer patients have now been approved to use psilocybin to treat end-of-life distress. These patients will be the first to legally use the psychedelic in Canada for almost half a century following...
by EmpathiCSubstanceS | Apr 25, 2021 | Cannabis Marijuana, CBC, MDMA Sassafras Molly
A new study, led by researchers from University College London, is offering some of the first robust evidence showing how cannabidiol (CBD), a key compound in cannabis, increases cerebral blood flow in memory processing regions of the brain such as the hippocampus....
by EmpathiCSubstanceS | Apr 25, 2021 | MDMA Sassafras Molly
Psychedelic pharmaceutical company MindMed is set to conduct a novel Phase 1 clinical trial exploring the subjective effects of combining LSD with MDMA. The primary goal of the prospective study is to investigate whether MDMA, a drug known to induce feelings of...
